

INVESTIGATOR-INITIATED STUDIES (IIS) AND EXTERNAL COLLABORATIVE RESEARCH (ECR) PROJECTS SUPPORTED BY BOEHRINGER INGELHEIM

Boehringer Ingelheim provides support to academic and clinical scientists for independent (IIS) or collaborative (ECR) research projects related to ILDs

There are **104** ongoing studies with **29** new studies approved in **2020** These include **25** interventional, **66** non-interventional, and **13** preclinical studies



Projects span IPF, SSc-ILD and a broad range of other ILDs; in 2020, several COVID-19 research studies commenced

Key studies currently in progress are outlined below

INTERVENTIONAL STUDIES

IPF		COVID-19	
	Nintedanib clinical trials High oxygen delivery to preserve exercise capacity in patients treated with nintedanib <i>C Ryerson</i> 88	NIN-2015-002	
	Nintedanib clinical trials Carboplatin plus nab-paclitaxel with or without nintedanib for IPF associated with advanced NSCLC <i>I Okamoto</i> 170	NIN-2016-009	
	Nintedanib clinical trials Continuation of nintedanib after single lung transplantation in IPF subjects <i>J Galli</i> 20	NIN-2017-016	
		Nintedanib clinical trials Nintedanib for the treatment of SARS-Cov-2-induced pulmonary fibrosis <i>B Crestani</i> 458	NIN-2020-011
		Nintedanib clinical trials Nintedanib for sub-acute lung injury in COVID-19 patients <i>M Padilla</i> 120	ECR_2020_00002060
AUTOIMMUNE ILDs		OTHER ILDs	
	Nintedanib clinical trials Tolerability and safety of nintedanib in myositis-associated ILD <i>D Assayag</i> 22	NIN-2018-023	
		Nintedanib clinical trials Nintedanib in lung transplant recipients with BOS <i>O Brugière</i> 80	NIN-2016-012
		Nintedanib clinical trials Nintedanib in patients with BOS following HSCT <i>K Hostettler</i> 40	NIN-2016-029
EXPOSURE-RELATED ILDs			Nintedanib clinical trials Nintedanib in the treatment of progressive LAM <i>S Harari</i> 26
	Nintedanib clinical trials Nintedanib in patients with progressive fibrosing coal mine dust-induced ILD <i>R Zulfikar</i> 160	ECR_2020_00001864	
	Nintedanib clinical trials The nintedanib in progressive pneumoconiosis trial <i>D Yates</i> 50	NIN-2018-020	
	Nintedanib clinical trials Safety and efficacy of nintedanib in slowing disease progression in silicosis <i>M Kramer</i> 40	NIN-2016-002	
			Pulmonary rehabilitation and exercise studies Characterizing and enhancing physical activity in patients with ILD <i>T Troosters</i> 160
			Studies of diagnostic, prognostic and monitoring methods Early detection of progressive fibrosis in patients with ILAs <i>L Hariri</i> 20
		ECR_2020_00002025	

NON-INTERVENTIONAL STUDIES

IPF		COVID-19	
	Biomarker studies Analysis of peptide splicing variants as a biomarker for progression of PF <i>J Lasky</i> 80	IIS_2020_00001781	
	Radiology and imaging studies Analysis of CT scans using deep learning to improve assessment of lung fibrosis <i>S Humphries</i> 1500	ECR_2020_00001796	
	Registry studies Neighborhood disadvantage and air pollution effects on clinical outcomes and the epigenome of patients with fibrotic ILDs <i>S Nourae</i> 5000 400 used for methylation profiling	IIS_2020_00001823	
			Biomarker studies Post-COVID-19 hypoxemic respiratory failure residual pathophysiologic outcomes <i>R Kaner</i> 300
			Natural history and pathogenesis studies Natural history, pathogenesis and regulation of pulmonary fibrosis induced by SARS-CoV-2 infection <i>M Molina-Molina</i> 120
			Other studies Outcome prediction using AI-based image evaluation in coronavirus <i>S Walsh</i> 5000
			Registry studies Development of ILD in patients with severe SARS-CoV-2 infection <i>I Tancevski</i> 200
		NIN-2020-012	
AUTOIMMUNE ILDs		OTHER ILDs	
	Biomarker studies ILD in early RA <i>J Solomon</i> 72	NIN-2017-015	
	Biomarker studies Novel biomarkers in RA-ILD <i>J Lee</i> 120	NIN-2018-014	
	Other studies The lung microbiome and lung metabolome in RA-ILD <i>K Demoruelle</i> 120	IIS_2020_00001855	
			Natural history and pathogenesis studies Familial fibrosis <i>R Borie</i> 150
	Radiology and imaging studies Validation of highly sensitive LUS interpretation criteria for the detection and management of ILD in patients with CTD <i>L Chung</i> 140	NIN-2019-006	
	Registry studies Pulmonary fibrosis and rheumatoid arthritis – screening and early diagnosis <i>L Erlacher</i> 100	NIN-2020-007	
	Registry studies The gut microbiome as a screening tool for ILD in SSc <i>E Volkman</i> 300	IIS_2020_00001917	
	Studies of prognostic indicators Predictors for the development and progression of ILD in SSc <i>M Kreuter</i> 3240	NIN-2016-006	
			Biomarker studies Exhaled breath analysis as a biomarker for diagnosis and disease progression in fibrotic ILD <i>M Wijsenbeek</i> 400
			Natural history and pathogenesis studies Early recognition of pulmonary parenchymal involvement in patients with systemic diseases bearing a risk for ILD <i>G Kovacs</i> 912
			Radiology and imaging studies Accuracy of diagnostic-support artificial intelligence and specialist interpretation in the early detection of interstitial pneumonia <i>H Chiba</i> 8844
			Registry studies I-FILE: A multinational patient-led registry in fibrotic ILDs using eHealth technology <i>M Wijsenbeek</i> >500
			Studies of prognostic indicators Hypersensitivity pneumonitis – disease progression characterization <i>L Kawano-Dourado</i> 150
		NIN-2020-004	